Clinical Trial Update: CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients [Phase 3]

View source ↗

Summary

A Phase 3 CAPPA-2 trial evaluating cisplatin added to gemcitabine in poor-performance advanced non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Platinol (cisplatin)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: TERMINATED